Navigation Links
Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
Date:11/8/2007

LOS ANGELES, Nov. 8 /PRNewswire-FirstCall/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development of molecular diagnostic tests for cancer, today announced it will release its third quarter and nine-month 2007 financial results in a press release on Wednesday, November 14, 2007.

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the ability of the Company to make its ERCC-1 molecular diagnostic test available in the first quarter of 2008, or at all, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE Response Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Study identifies key player in the bodys immune response to chronic stress
3. Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Merck & Co., Inc. Response to Todays New York Medicaid Suit
6. Maternal depression and controlling behavior associated with increased stress response in infants
7. Family history of alcoholism affects response to drug used to treat heavy drinking
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... There was a time when tampons and pads were the only options ... turning to menstrual cups, like Lunette . To make that time of the month ... in this catchy video ! , It’s easy to see why Lunette is ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today American University of Antigua ... Medicine announced the AUA-FIU Global MD Program. Students in the Global MD ... and a Certificate of Completion from the FIU Herbert Wertheim College of Medicine ...
(Date:5/25/2016)... ... ... CloudLIMS, joins an elite number of companies that have earned a spot ... by CIOReview. , In a deliberate session with the honorary industrial experts, a list ... concluded with. The positioning is based on evaluation of CloudLIMS’ specialties in Automated Sample ...
(Date:5/25/2016)... ... , ... Cheryl Bowker of Bowker Insurance Group has been presented with one ... Award. McKenna ran one of Allstate’s most successful agencies for 48 years, but it ... him. The award named for him is not given every year, but only when ...
(Date:5/25/2016)... ... May 25, 2016 , ... Afrimesure ... from medical and pharmaceutical, to food and HVAC facilities. Their knowledgeable staff also ... , For medical applications, Afrimesure offers a variety of MadgeTech systems available ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to help doctors ... a global scale. Medical professionals from Europe , ... the US have already signed up for the app, which combines ... environment. Education  "Imagine a doctor for Medicines ... at Harvard to treat a bomb victim via live streaming - ...
(Date:5/23/2016)... PUNE, India , May 23, 2016 ... is spread across 163 pages, profiles 12 companies and ... 280 tables and figures on the industry and its ... study that is comprehensive in nature, details the current ... of the industry including definitions, classifications, applications and industry ...
(Date:5/23/2016)... YORK , May 23, 2016 ... Spectrometry Market Size, Share, Development, Growth and Demand ... (Hybrid, Single and Other), by Application (Drug Discovery ... by End Users (Pharmaceuticals, Life Science and Biotechnology, ... by P&S Market Research, the global mass ...
Breaking Medicine Technology: